Bodhi Tree Biotech Amends 10-Q, Confirms Smaller Reporting Status

Ticker: BDTB · Form: 10-Q/A · Filed: Jul 28, 2025 · CIK: 2041531

Sentiment: neutral

Topics: 10-Q/A, Regulatory Filing, Smaller Reporting Company, Emerging Growth Company, Biotechnology, SEC Compliance, Amendment

Related Tickers: BDTB

TL;DR

**BDTB's 10-Q/A is a non-event, merely a regulatory housekeeping amendment confirming its small-cap status, offering no new financial insights.**

AI Summary

Bodhi Tree Biotechnology Inc. filed a 10-Q/A for the quarter ended March 31, 2025, indicating an amendment to its previous quarterly report. The filing confirms the company's status as a non-accelerated filer, a smaller reporting company, and an emerging growth company. It also states that the company is not a shell company. The amendment itself does not provide specific financial figures for revenue or net income, focusing instead on regulatory compliance and company classification. The document confirms Bodhi Tree Biotechnology Inc. has filed all required reports under Section 13 or 15(d) of the Exchange Act during the preceding 12 months and has been subject to such filing requirements for the past 90 days. Furthermore, the company has submitted every Interactive Data File required by Rule 405 of Regulation S-T during the preceding 12 months. The filing does not detail any key business changes, specific risks, or strategic outlook beyond its regulatory status.

Why It Matters

This 10-Q/A filing primarily clarifies Bodhi Tree Biotechnology Inc.'s regulatory status, confirming it as a smaller reporting company and an emerging growth company. For investors, this means the company operates under less stringent reporting requirements, which can impact transparency and the depth of available financial data compared to larger competitors. Employees and customers are less directly affected by this specific amendment, but the company's ongoing compliance with SEC regulations is crucial for its long-term stability and market perception. The competitive context suggests that smaller biotech firms often face higher scrutiny regarding their operational transparency and financial health.

Risk Assessment

Risk Level: low — The risk level is low because this 10-Q/A is an amendment (Amendment No. 1) that primarily clarifies the company's regulatory status, such as being a 'smaller reporting company' and an 'emerging growth company,' rather than disclosing new adverse financial or operational information. The filing confirms the company has met all SEC reporting requirements, indicating good compliance.

Analyst Insight

Investors should view this 10-Q/A as a procedural update, not a catalyst for immediate action. Focus on the original 10-Q for financial performance and operational details, as this amendment provides no new material financial data. Maintain your existing position or research further into the company's core business.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of Bodhi Tree Biotechnology Inc.'s 10-Q/A filing?

The 10-Q/A filing by Bodhi Tree Biotechnology Inc. is an amendment (Amendment No. 1) to its quarterly report, primarily to clarify its regulatory status as a non-accelerated filer, a smaller reporting company, and an emerging growth company for the quarter ended March 31, 2025.

Did Bodhi Tree Biotechnology Inc. report new financial results in this 10-Q/A?

No, the 10-Q/A filing for Bodhi Tree Biotechnology Inc. does not contain new financial results for revenue or net income. It focuses on regulatory compliance and company classification, amending a previously filed 10-Q for the quarter ended March 31, 2025.

What is Bodhi Tree Biotechnology Inc.'s filing status according to the 10-Q/A?

According to the 10-Q/A filed on July 28, 2025, Bodhi Tree Biotechnology Inc. is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company. It also confirmed it is not a shell company.

Has Bodhi Tree Biotechnology Inc. complied with SEC reporting requirements?

Yes, the 10-Q/A states that Bodhi Tree Biotechnology Inc. has filed all reports required by Section 13 or 15(d) of the Exchange Act during the preceding 12 months and has submitted every Interactive Data File required by Rule 405 of Regulation S-T.

What does 'smaller reporting company' mean for Bodhi Tree Biotechnology Inc. investors?

For investors, Bodhi Tree Biotechnology Inc. being a 'smaller reporting company' means it is subject to scaled-down disclosure requirements, potentially providing less detailed financial and operational information compared to larger, accelerated filers. This can impact the depth of analysis possible.

What is the fiscal year end for Bodhi Tree Biotechnology Inc.?

The fiscal year end for Bodhi Tree Biotechnology Inc. is September 30, as stated in the company data section of the 10-Q/A filing.

Where is Bodhi Tree Biotechnology Inc.'s principal executive office located?

Bodhi Tree Biotechnology Inc.'s principal executive office is located at 4125 Blackhawk Plaza Circle, Suite 172, Danville, CA 94506, with a telephone number of (925) 406-4528.

Does the 10-Q/A indicate any new risks for Bodhi Tree Biotechnology Inc.?

The 10-Q/A filing for Bodhi Tree Biotechnology Inc. does not introduce any new specific risks. It is an amendment focused on regulatory classification and compliance, not on operational or financial risk factors.

What is the Central Index Key (CIK) for Bodhi Tree Biotechnology Inc.?

The Central Index Key (CIK) for Bodhi Tree Biotechnology Inc. is 0002041531, which is used by the SEC to identify the company.

How does being an 'emerging growth company' affect Bodhi Tree Biotechnology Inc.?

As an 'emerging growth company,' Bodhi Tree Biotechnology Inc. benefits from certain exemptions from reporting requirements, such as reduced disclosure obligations and an extended transition period for complying with new or revised financial accounting standards, as provided by Section 13(a) of the Exchange Act.

Industry Context

Bodhi Tree Biotechnology Inc. operates within the broader biotechnology and potentially management consulting sectors, as indicated by its SIC code. The biotechnology industry is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies in this space often face intense competition from both established players and emerging startups, with success heavily reliant on innovation and intellectual property protection.

Regulatory Implications

As a non-accelerated filer, smaller reporting company, and emerging growth company, Bodhi Tree Biotechnology Inc. benefits from scaled disclosure requirements. However, it must consistently meet its filing obligations under Section 13 or 15(d) of the Exchange Act and submit all required Interactive Data Files. Failure to maintain these compliance standards could lead to regulatory scrutiny or penalties.

What Investors Should Do

  1. Review prior filings for financial details.
  2. Monitor future filings for operational and financial updates.

Key Dates

Glossary

10-Q/A
An amended quarterly report filed with the SEC, used to correct or supplement information previously filed in a 10-Q. (This filing is an amendment to Bodhi Tree Biotechnology Inc.'s quarterly report.)
Non-accelerated filer
A filer that does not meet the requirements for accelerated filer status, typically based on public float. (Indicates Bodhi Tree Biotechnology Inc.'s regulatory classification, affecting its filing obligations.)
Smaller reporting company
A company that meets certain criteria regarding public float and revenue, allowing for scaled disclosure requirements. (Bodhi Tree Biotechnology Inc. qualifies as a smaller reporting company, impacting the level of detail required in its SEC filings.)
Emerging growth company
A company that has total annual gross revenues of less than $1.235 billion during its most recently completed fiscal year. (Bodhi Tree Biotechnology Inc. is classified as an emerging growth company, potentially benefiting from extended transition periods for accounting standards.)
Shell company
A company with no or nominal operations, and with the assets consisting of cash, cash equivalents, and short-term investments. (The filing explicitly states Bodhi Tree Biotechnology Inc. is not a shell company, indicating it has ongoing operations.)
Interactive Data File
Electronic files submitted to the SEC in a standardized format (XBRL) that allows for automated processing and analysis. (The company confirms it has submitted all required Interactive Data Files, demonstrating compliance with modern SEC filing requirements.)

Year-Over-Year Comparison

This filing is an amendment (Amendment No. 1) to a previous 10-Q report for the quarter ended March 31, 2025. As it is an amendment and does not introduce new financial data, a direct comparison of key metrics like revenue growth or margin changes to a prior year's filing is not possible based solely on this document. The primary purpose of this amendment appears to be confirmation of the company's filer status and compliance with SEC regulations, rather than reporting updated financial performance.

Filing Details

This Form 10-Q/A (Form 10-Q/A) was filed with the SEC on July 28, 2025 regarding Bodhi Tree Biotechnology Inc (BDTB).

View full filing on EDGAR

View Full Filing

View this 10-Q/A filing on SEC EDGAR

View on Read The Filing